Europe and Rest of the World ("ROW") Generic Sales
Sales of generic products in Europe and the ROW through our PLIVA subsidiary were $196 million in the fourth quarter of 2007. Revenues were primarily driven by sales of PLIVA products in the key markets of Germany, Croatia, Poland and Russia. Prior to the Company's acquisition of PLIVA in October 2006, Barr did not have any product sales in Europe or the ROW.
Proprietary Product Sales
The Company's proprietary product sales were $438 million for 2007, up 12% compared to $391 million in 2006. The increase was primarily attributable to higher sales of Plan B Over-the-Counter/Rx, Adderall(R) IR and SEASONIQUE(R) extended-cycle oral contraceptive, all of which were launched in the second half of 2006. These increases more than offset lower sales of SEASONALE(R) extended-cycle oral contraceptive, which faced generic competition in September 2006 following the expiration of three years of market exclusivity.
For the fourth quarter of 2007, proprietary product sales were $122 million, compared to $98 million in the prior year period. The increase was primarily attributable to higher sales of Plan B and SEASONIQUE and more than offset the expected lower sales of SEASONALE.
Alliance and Development Revenue
During 2007, the Company reported alliance and development revenue of
$122 million, compared to $131 million in 2006. For the fourth quarter of
2007, alliance and development revenue was $28 million, as compared to $34
million in the prior year period. The decrease for the year and for the
fourth quarter ended December 31, 2007 primarily reflects a decline in
income derived from the Company's share of the
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved